	US 12,296,003 B2
	Bovine herpesvirus type 1 (BoHV-1) vector against bovine respiratory disease complex
Shafiqul I. Chowdhury, Baton Rouge, LA (US)
Assigned to BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, Baton Rouge, LA (US)
Filed by Shafiqul I. Chowdhury, Baton Rouge, LA (US)
Filed on Jul. 9, 2021, as Appl. No. 17/372,044.
Application 17/372,044 is a continuation of application No. 15/780,900, granted, now 11,083,787, previously published as PCT/US2016/064775, filed on Dec. 2, 2016.
Claims priority of provisional application 62/262,450, filed on Dec. 3, 2015.
Prior Publication US 2022/0062407 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/245 (2013.01) [A61K 39/12 (2013.01); A61K 39/39 (2013.01); C07K 14/005 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/543 (2013.01); A61K 2039/552 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/16743 (2013.01); C12N 2710/16771 (2013.01); C12N 2760/18534 (2013.01); C12N 2770/24334 (2013.01)]

25 Claims

1. A mutant BoHV-1 recombinant vector (BOHV-1) comprising at least one heterologous antigen inserted therein, wherein the mutant BoHV-1 vector has:

a) a deletion of a cytoplasmic tail of envelope glycoprotein gE (gE-CT),

b) a deletion of an entire Us9 envelope protein, and

c) a deletion of the envelope protein UL49.5 residues 30-32, the cytoplasmic tail residues 80-96 or a combination thereof,

wherein the at least one heterologous antigen is a BRSV F antigen having at least 95% amino acid sequence identity to SEQ ID NO: 15, 16, 17, 20, 22, or 24 or a BRSV G antigen having at least 95% amino acid sequence identity to SEQ ID NO:26, 28, 29, 31, 34, or 36, and

wherein the BRSV F antigen or the BRSV G antigen is inserted in the mutant BOHV-1 recombinant vector at the gE-CT/Us9 deletion site.